|
J Biol Chem, Vol. 274, Issue 30, 21085-21094, July 23, 1999
Abnormal Cardiac Structure and Function in Mice Expressing
Nonphosphorylatable Cardiac Regulatory Myosin Light Chain 2*
Atsushi
Sanbe ,
Jason G.
Fewell ,
James
Gulick ,
Hanna
Osinska ,
John
Lorenz§,
D. Greg
Hall¶,
Lisa A.
Murray ,
Thomas R.
Kimball ,
Sandra A.
Witt , and
Jeffrey
Robbins **
From the Department of Pediatrics, Division of
Molecular Cardiovascular Biology and Department of Pediatrics,
Division of Cardiology, Children's Hospital Research Foundation,
Cincinnati, Ohio 45229-3039, the ¶ Department of Pathology,
University of Georgia College of Veterinary Medicine, Athens, Georgia
30603, and the § Department of Molecular and Cellular
Physiology, University of Cincinnati, Cincinnati, Ohio 45267-576
 |
ABSTRACT |
A role for myosin phosphorylation in modulating
normal cardiac function has long been suspected, and we hypothesized
that changing the phosphorylation status of a cardiac myosin light chain might alter cardiac function in the whole animal. To test this
directly, transgenic mice were created in which three potentially phosphorylatable serines in the ventricular isoform of the regulatory myosin light chain were mutated to alanines. Lines were obtained in
which replacement of the endogenous species in the ventricle with the
nonphosphorylatable, transgenically encoded protein was essentially
complete. The mice show a spectrum of cardiovascular changes. As
previously observed in skeletal muscle, Ca2+
sensitivity of force development was dependent upon the phosphorylation status of the regulatory light chain. Structural abnormalities were
detected by both gross histology and transmission electron microscopic
analyses. Mature animals showed both atrial hypertrophy and dilatation.
Echocardiographic analysis revealed that as a result of chamber
enlargement, severe tricuspid valve insufficiency resulted in a
detectable regurgitation jet. We conclude that regulated phosphorylation of the regulatory myosin light chains appears to play
an important role in maintaining normal cardiac function over the
lifetime of the animal.
 |
INTRODUCTION |
The roles of the regulatory myosin light chains
(RLCs)1 and the reversible
post-translational modifications they undergo in striated muscle are
beginning to be defined. In skeletal muscle, a serine at the amino end
of the protein can be phosphorylated by a sarcoplasmic kinase (1), and
it is now clear that RLCs in the different striated muscles are
phosphorylated to differing degrees, leading presumably to different
physiological effects. In smooth muscle, RLC phosphorylation by myosin
light chain kinase (MLCK), which is activated by a
Ca2+/calmodulin-dependent pathway, is
responsible for initiating muscle contraction (2, 3). However, in
skeletal and cardiac muscle, in which the thin, rather than thick,
filament mediates control of contraction, RLC phosphorylation does not
activate contraction but appears to play a modulatory role. In skinned
skeletal muscle fibers, RLC phosphorylation increases sensitivity to
activating Ca2+ such that there is a significant leftward
shift in the force-Ca2+ relationship (4-6). Increased RLC
phosphorylation in skeletal muscle is also associated with potentiation
of isometric twitch tension with repeated activation and inactivation
of contraction (7, 8), rate of force production (9-11), and maximum
Ca2+-stimulated MgATPase activity (12).
The mechanistic basis for the effects of RLC phosphorylation in
striated muscle is hypothesized to be a lessening of the weak interaction of the myosin head with the myosin backbone and is probably
due to a net charge change in a critical region of the protein (13).
Upon phosphorylation, the myosin heads move away from the backbone to a
position closer to actin, which presumably increases the rate at which
myosin-actin interactions occur. Recently, the physiological importance
of RLC phosphorylation in striated muscle was addressed by examining
the in vivo effects of RLC mutant proteins in the indirect
flight muscle of Drosophila (14). Phosphorylatable serine
residues were replaced with alanines, and the mutated proteins were
introduced into a null RLC background. The resultant flies showed
normal myofibrillogenesis but had reduced power output and flight
ability resulting from a marked reduction in the stretch activation of
the indirect flight muscle.
Little is known about the role RLC2 phosphorylation plays in
maintaining normal mammalian cardiac function. In rats, increased RLC
phosphorylation occurs in response to increases in beat frequency and/or LV pressure due to exercise or inotropic agents (15, 16). This
response may help maintain force production and stroke volume in the
face of an increased rate of relaxation. However, the response is
attenuated or absent in the mouse heart after similar exercise regimens
(17). Changes in RLC phosphorylation in ischemic rabbit hearts have
been noted (18), and in some patients with heart failure, decreases in
light chain phosphorylation occurred (19).
In this study, we examined the physiological role of RLC
phosphorylation in the heart by transgenically overexpressing a mutated form of RLC2v (ventricular regulatory myosin light chain) that could
not be phosphorylated. Multiple lines of transgenic (TG) mice were
created in which the endogenous atrial and ventricular isoforms of RLC2
were replaced with a ventricular form in which alanines were
substituted for the phosphorylatable serines at residues 14, 15, and
19. Analyses of these animals at the molecular, cellular, whole organ,
and animal levels confirm the importance of regulated phosphorylation
of the myosin light chains in maintaining normal cardiac function.
 |
EXPERIMENTAL PROCEDURES |
Transgene Construction--
A previously isolated full-length
murine RLC2v cDNA was used as a starting template (20). Primers
with SalI sites engineered at the termini were made to the
3'- and 5'-untranslated regions of the cDNA. The 5' primer also
contained the mutated bases necessary to change the serines at residues
14, 15, and 19 to alanines (Fig. 1A). The polymerase chain
reaction product was sequenced, and the fragment was linked to the
mouse -myosin heavy chain promoter. The final construct, RLC2v(P ),
was digested free of vector sequence with NotI, purified
from agarose, and used to generate transgenic mice as described
(20).
Transcript Analysis--
Total ventricular RNA was prepared from
freshly isolated hearts obtained from 8-16-week-old mice euthanized by
CO2 asphyxiation. Samples were homogenized in Tri-Reagent
(Molecular Research Center, Cincinnati, OH), and RNA was extracted
according to the manufacturer's protocol. For each analysis, 1.5 µg
of total RNA was loaded onto a nitrocellulose membrane using a dot
blotting apparatus (Bio-Rad). Hybridizations using
32P-end-labeled oligonucleotides were performed as
described previously (21). Oligonucleotide sequences that were used as
probes (glyceraldehyde-3-phosphate dehydrogenase, -skeletal actin,
atrial natriuretic factor (ANF), -myosin heavy chain (MyHC), and
phospholamban have been published (22). A 51-base oligonucleotide,
specific for RLC2v consisted of the sequence
5'-CTGAGGCTGTGGTTCAGGGCTCAGTCCTTCTCTTCTCCGTGGGTAATGATT-3', and the
oligonucleotide
5'-AGGTGTGTTGCTAACAACGCAGATGCACGCACCCGAACACCCTTATATTTCTGCAAATGG-3', specific for the sarcoplasmic reticulum ATPase was also used. Hybridization signals were identified and quantitated using a STORM
PhosphorImager (Molecular Dynamics, Inc.).
Myofilament Protein Analyses--
For SDS-PAGE, the left
ventricular apex and atrial flaps were obtained from euthanized
RLC2v(P ) TG and nontransgenic (NTG) mice. Myofibrillar sample
preparation, gel preparation, electrophoretic conditions, and gel
staining have been described (17). Samples used for two-dimensional gel
electrophoresis were prepared as described by Kirschbaum et
al. (23). Cylindrical polyacrylamide gels (2 mm) for isoelectric
focusing were prepared as described by O'Farrell (24) using Bio-Rad
ampholytes (2% (v/v) final concentration) with a restricted gradient
of pH 4-6. Electrophoresis was performed at 500 V for 10 min and then
at 750 V for 3.5 h. Gels were removed from the tubes and
equilibrated in a solution containing Tris buffer (62.5 mM,
pH 6.8), 1% (w/v) SDS, and 5% (v/v) -mercaptoethanol for
approximately 5 min. Electrophoresis in the second dimension slab gel
(16% polyacrylamide; 29:1 acrylamide to bisacrylamide with a 5%
stacking gel; 29:1 acrylamide to bisacrylamide) was carried out in the
presence of 0.1% SDS. Gels were stained with colloidal blue (Sigma).
The phosphorylation state of fibers used in the mechanical studies was
tested by Western blot analysis as described (17). Each sample
consisted of two ventricular fiber bundles homogenized in sample buffer
(8 M urea, 18 mM Tris (pH 8.5), 20.7 mM glycine, 9.3 mM dithiothreitol, 4.6% (v/v)
saturated sucrose, and 0.004% (w/v) bromphenol
blue).2
Electron Microscopy and Histology--
The methods used for
ultrastructural analysis have been described (17). For histological
examination, hearts were briefly perfused with 4% paraformaldehyde in
phosphate-buffered saline and then removed and further fixed in 4%
paraformaldehyde. The methods for paraffin embedding, sectioning, and
staining have been described (17).
Measurements of Fiber Function--
Standard methods for
measuring force development from skinned muscle fibers were adapted for
mouse cardiac fibers (25). To examine the effects of myosin light chain
phosphorylation on the pCa-force relationship in
vitro, skinned fibers were treated with myosin light chain kinase
and calmodulin. After measurements of the pCa-force
relationship (first contraction), the fiber was incubated in relaxing
solution (pCa 8.0) plus 2 µM calmodulin and
0.15 µM of truncated MLCK (kindly provided by Dr. J. T. Stull, University of Texas Southwestern Medical Center) for 10 min
and then in a solution with a pCa of 5 plus 2 µM calmodulin and 0.15 µM truncated MLCK
for 10 min. The fibers were relaxed for 2 min, and the
pCa-force relationship was measured (second contraction). As
a control protocol, fibers were exposed to a double sequence of
contraction without calmodulin and MLCK. To examine the effects of
myosin light chain phosphorylation on myofibrillar MgATPase activity
in vitro, the myofibril was incubated in the following medium: 60 mM KCl, 60 mM imidazole, 6 mM MgCl2, 5 mM EGTA, 5.33 mM ATP at pH 7.0 (pCa = 5) containing 2 µM calmodulin and 0.15 µM truncated myosin
light chain at 23 °C for 30 min. The myofibril was washed with
incubation medium but with a pCa = 8.0, and
Ca2+-stimulated MgATPase activity was measured. The 5-min
reaction was initiated with the addition of the sample at 23 °C and
stopped with 15% trichloroacetic acid. The reaction mixture was
centrifuged, and inorganic phosphate was measured in the supernatant
fraction. The Ca2+-stimulated MgATPase activity was
estimated by subtracting the activity at pCa = 8.0.
Intact Animal Model--
Assessment of left ventricular function
was performed as follows. Mice were anesthetized with intraperitoneal
injections of 50 µg/g, body weight (BW), ketamine and 100 µg/g, BW,
thiobutabarbital (Inactin, Research Biochemicals International, Natick,
MA) and placed on a thermally controlled surgical table. Following
tracheostomy, the right femoral artery and vein were cannulated with
polyethylene tubing for measuring systemic arterial pressure and for
the infusion of experimental drugs. A 1.4F Millar Mikro-Tip transducer
(Millar Instruments, Houston, TX) was inserted in the right carotid
artery and advanced into the left ventricle for measurement of LV
pressure and dP/dt. Cardiovascular responses to
increasing doses of dobutamine were determined during 3-min constant
infusions (0.1 µl/min/g, BW), and average values were determined
during the final 30 s of each infusion. At the end of each
dose-response protocol, a bolus dose of propranolol (100 ng/g, BW) was
administered to evaluate baseline cardiac function in the absence of
endogenous -adrenergic activity. Pressure signals were recorded and
analyzed using a MacLab 4/s data acquisition system at a sampling rate
of 1000 samples/s/channel.
Echocardiography--
Echocardiography was performed using a
Hewlett Packard Sonos 5500 Ultrasound System equipped with a 12-MHz
transducer (Andover, MA). In order to place the heart in the mid-field
of the ultrasound sector where axial resolution is optimal, the
transducer was fashioned with a latex balloon filled with warm acoustic
gel producing a 1-cm standoff between the chest wall and the transducer
face. Two-dimensionally guided M-mode echocardiography of the left
ventricle from its short axis was recorded on an optical disc and a
strip chart at a speed of 100 mm/s.
 |
RESULTS |
Transgenic Expression of Nonphosphorylatable RLC2--
The object
of this study was to ablate RLC2 phosphorylation in the heart. In
striated muscle, MLCK can phosphorylate serine 15 (1, 26). In
Drosophila, serines 66 and 67 can be phosphorylated by the
enzyme (27). These two residues are analogous to serines 14 and 15 in
the mouse (Drosophila RLC has an N-terminal extension that
is absent in mammalian RLC), suggesting that both residues are
potential enzyme substrates. In smooth muscle, both threonine 18 and
serine 19 can be phosphorylated by MLCK (28), and sequence similarities
between the smooth and striated muscle RLCs suggest that serine 14 in
skeletal muscle is also a target for MLCK phosphorylation. An
additional consideration in the construct's design was that other
kinases such as Rho kinase and protein kinase C have the ability to
phosphorylate RLC2 at serine 15 as well as at other amino acid residues
(5, 29, 30). Thus, to ensure that phosphorylation would not occur on
the transgenically encoded protein, serines 14, 15, and 19 were each
mutated and replaced by alanine (Fig. 1A). Multiple clones were
sequenced to exclude polymerase chain reaction-induced errors. Except
for the mutated residues, the consensus sequence was identical to that
previously used to make TG mice (20). Three TG founders were identified
and used to establish stable lines by outbreeding to NTG animals. In
all cases, the analyses below were carried out on transgenic
heterozygotes in order to minimize the possibility of confounding the
phenotype through insertional mutagenesis. RLC2v expression at the
transcript level was quantitated by dot blot analyses with
transcript-specific oligonucleotides (Fig. 1B). TG
transcript levels were quite modest, ranging from 1.33- to 2.5-fold
above that of the endogenous message and were constant across all four
cardiac compartments.2

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 1.
RLC2v(P ) transgene construct and
transcriptional expression. A, the wild type
ventricular isoform of the regulatory myosin light chain 2 (RLC2v) was
mutated such that the phosphorylatable serines at amino acid
residues 14, 15, and 19 were replaced by alanines. The sequences shown
correspond to amino acids 1-21. Identical nucleotide bases are
indicated with a dot. The locations of the amino acid
changes are numbered. The cDNA was placed in the
-MyHC promoter cassette and used to generate transgenic mice as
described under "Experimental Procedures." Three lines of mice were
subsequently selected for study. B, RNAs were isolated from
the ventricles, and the RNA abundance of the transgene, relative to the
endogenous RLC2v (set at 1), was determined by dot blot analyses as
described previously (22). Three 4-month-old males were used for each
of the RNA isolations.
|
|
We were interested in determining if there were changes in heart
morphology in the RLC2v(P ) TG mice. When the RLC of
Drosophila indirect flight muscles was replaced by a
nonphosphorylatable variant, no overt changes in overall muscle
organization or architecture could be detected (14). In contrast to the
insect data, hearts from adult mice derived from the higher expressing
lines 21 and 35 both showed hypertrophied and dilated atria when
compared with line 42, which expressed only low levels of the transgene
or NTG hearts (Fig. 2A).
Multiple hearts (4-8 hearts) from both lines 21 and 35 showed similar
gross morphology, ruling out the possibility that the observed
phenotype was due to an insertional mutagenic event. Sections comparing
ventricular free walls derived from wild type or NTG versus
RLC2v(P ) animals indicated that some mild cardiomyocyte disarray
could be detected in the latter (Fig. 2C). This mild
pathology was apparent in both lines 21 and 35 but not in the line that
expressed low levels of the transgene (line 42).2 In an
attempt to define more precisely any LV hypertrophy that might be
occurring, 10-week TG (line 21) and NTG hearts were dissected, and the
weights of the septa and LV free walls were determined (Table
I). The data show a trend toward septal
hypertrophy, while the LV free wall weights are unaffected. To confirm
the lack of overt hypertrophy in the ventricles, a detailed
morphometric analysis was carried out on hearts from NTG and TG lines
expressing either wild type RLC2v or RLC2v(P ) (lines 21 and 35).
Multiple sections were cut from five blocks derived from two hearts
from each line and myocyte density, diameter, and myocyte volume
density determined for the LV and RV free wall, as well as the septum.
No statistically significant differences between either of the TG
lines, as compared with the NTG hearts, were observed.2

View larger version (124K):
[in this window]
[in a new window]
|
Fig. 2.
Cardiac structural analyses.
A, typical whole mounts of intact hearts derived from a NTG
animal and lines 42, 35, and 21. Line 42, because of low transgene
expression (Fig. 1), only had 50% replacement of the normal protein
with the nonphosphorylatable RLC2v(P ), while lines 21 and 35 had
essentially complete replacement as shown in Fig. 3. The hearts shown
are representative of multiple (4-8) hearts, which have been examined
from each line. Note the significant increase in atrial size in hearts
derived from lines 21 and 35. These hearts typically showed biatrial
dilation and dilated right ventricles. In some cases, organized atrial
thrombi were also found. B and C, shown are
hemotoxylin- and eosin-stained sections derived from LV free walls of
NTG (B) and TG (C) hearts (line 21). When
compared with the NTG-derived section, the TG material shows mild
ventricular myocyte abnormalities. Line 35 showed an identical
phenotype, while line 42 appeared normal. All hearts were derived from
3-4-month-old males.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Normalized heart weights for line 21 mice
n = 3. All values are means ± S.E., Student's
t test was used to determine significant differences.
|
|
Protein Expression--
Expression of the mutated protein was
first analyzed by examining myofilament proteins derived from the atria
of TG animals. Previously, we overexpressed wild type RLC2v in the
mouse heart, resulting in complete replacement of atrial RLC2a, while
ventricular levels of RLC2v remained constant (17, 20, 31). Those
studies showed that overexpression of the ventricular isoform in the
atrial compartment resulted in small changes in whole heart function, with modest decreases in the rate of force development and relaxation. However, the mice exhibited no cardiac hypertrophy or chamber dilation.
Protein from these mice (line 97) was included as controls in the
following analyses. The ventricular and atrial isoforms of RLC2 can be
resolved by SDS-PAGE, and examination of the atrial myofibrillar
protein composition of juvenile and adult mice shows a progressive
replacement of RLC2a with the mutated RLC2v (Fig. 3A). In young mice (3 weeks
old), the highest expressing lines (21 and 35) show 50% replacement,
while line 42 shows little or no replacement. However, by 3-4 months
the two high expressing lines show complete replacement, while line 42 shows approximately 50% replacement. Note that for both the RLC2v and
RLC2v(P ) overexpressors, no overt changes in contractile protein
stoichiometry occurred (Fig. 3A). To determine ventricular
replacement, a gel system capable of resolving RLC2v from RLC2v(P )
was developed. A 21% SDS-PAGE resolved the 48-dalton differences in
size between the mutated and endogenous proteins (Fig. 3B).
The data show that both line 35 and 21 have a nearly complete RLC2v RLC2v(P ) shift, whereas there is little or no replacement in line 42. In all cases, the myofibril protein stoichiometries were maintained as
evidenced by no net increase in total RLC2v protein, a result
consistent with previous data obtained for the RLC2v(wt) overexpressors
(20). Because of the lack of a discernable gross cardiac phenotype in the low overexpressors (line 42) and essential identity observed between lines 21 and 35, both of which expressed identical levels of
the transgene and showed biatrial hypertrophy, the analyses carried out
below focused only on line 21.

View larger version (56K):
[in this window]
[in a new window]
|
Fig. 3.
Effects of transgene expression on myocardial
protein composition. A, in the left
panel, myofilament proteins were extracted from the atria of
3-week-old animals of the different lines, subjected to SDS-PAGE as
described under "Experimental Procedures," and stained with
colloidal blue. Line 97 is a TG line expressing wild type RLC2v in the
atria at levels such that the atrial isoform is completely replaced
(31). The right panel shows the degree of
replacement in the atria of adult (3-month) mice. Line 42 shows
approximately 50% replacement, while the other two, higher expressing
lines show complete replacement of RLC2a with RLC2v(P ), without
altering the levels of the other sarcomeric proteins. B,
quantitation of the degree of replacement in the ventricles of adult
transgenic mice. A gel system was developed that allowed resolution of
the RLC2v and RLC2v(P ) isoforms. In all experiments, samples were
derived from two or three 3-4-month-old males. The stained gels were
scanned, and the signal intensities were quantitated using NIH Image
(version 1.57). The corresponding levels of the endogenous RLC2 isoform
and RLC2v(P ) were determined for each line. Lines 21 and 35 show
complete replacement. MIX, equal amounts of protein from
line 21 and NTG mice were electrophoresed in order to confirm the
resolution of the gel system. Note that the mutated form (*) migrates
more slowly. As previously noted, in neither cardiac compartment could
an overt effect on the myofilament stoichiometry of the other
contractile proteins be detected.
|
|
To determine if detectable phosphorylatable RLC2v was left in TG
ventricles, we attempted to resolve the phosphorylated and unphosphorylated forms by PAGE but were unsuccessful. Therefore, the
RLC2v phosphorylated and unphosphorylated forms were separated by
two-dimensional gel electrophoresis (Fig.
4). The species corresponding to RLC2v
and the phosphorylated form were initially identified by Western blot
analysis; multiple analyses showed that in NTG ventricles, 10-30% of
the RLC2v is phosphorylated (Fig. 4, top panel).
In TG animals, phosphorylated RLC2v could not be detected. These data,
in conjunction with the SDS-PAGE analyses, indicate that not only is
phosphorylation completely ablated in the TG RLC2v(P ), but little
endogenous RLC2v remains in the adult ventricles of line 21 (and line
35)2 TG animals.

View larger version (151K):
[in this window]
[in a new window]
|
Fig. 4.
Two-dimensional gel electrophoresis of NTG
and line 21 TG ventricular samples. The arrows indicate
species corresponding to the phosphorylated and unphosphorylated forms
of RLC2v. Samples were derived from 2-3 4-month-old males.
ELC1v, ventricular essential light chain 1v. In the NTG
animals, approximately 20% of the RLC2v species migrate as a
phosphorylated species. No analogous species is present in the TG
protein preparation, indicating that no phosphorylation occurred at
other sites in the molecule.
|
|
Ultrastructure of Line 21 RLC2v(P ) Hearts--
In light of the
histological abnormalities observed in lines 21 (Fig. 2C)
and 35,2 we were interested in determining if there were
ultrastructural changes in the RLC2v(P ) TG mice. If the RLCs of
Drosophila indirect flight muscles are replaced by a
nonphosphorylatable variant, no changes at the ultrastructural level
take place (14). Hearts from line 21 animals were then chosen for
detailed ultrastructural study using transmission electron microscopy.
First, cursory screening of 1-µm epon resin sections from LV
fragments of TG mice revealed irregularly shaped cardiomyocytes, the
presence of vacuoles, and an irregular distribution of mitochondria
(data not shown). At the ultrastructural level, cardiomyocytes from TG
LVs revealed more striking abnormalities (Fig.
5). Normal NTG myocytes show tightly
packed sarcomeric arrays and clearly defined intercalated discs (Fig.
5A), while myofibril degeneration presents in the RLV2v(P )
cardiomyocytes. In many cases, sarcomeric organization is lost and the
intercalated discs are convoluted. Large interstitial spaces separate
the myocytes, and there is increased collagen deposition (Fig. 5,
B-D). Some myocytes, apparently in the final stages of
degeneration, were filled with vacuoles, although all had intact
sarcolemmal membranes.

View larger version (188K):
[in this window]
[in a new window]
|
Fig. 5.
Ultrastructural analysis of the left
ventricle. Shown are electron micrographs from sections taken of
adult line 21 hearts. A, longitudinal section from a
4.5-month-old NTG mouse. The myocytes show normal sarcomeric
organization with rows of mitochondria and regular invaginations of the
sarcolemma at the intercalated disc (ID). Perivascular areas
contain some collagen fibers (arrowhead). V,
blood vessel. B, a section from a 4.5-month-old TG mouse.
Wide interstitial areas with numerous processes (probably fibroblasts)
are apparent. A degenerating myocyte is adjacent to two normal cells.
The degenerating myocyte has no sarcomeric organization, few
mitochondria, and little sarcoplasmic reticulum. The visible
intercalated disc (ID) appears to be highly convoluted.
Several myelin figures (+) are present, not only in the degenerated
cell but also in the surrounding myocytes, suggesting that these cells
are in early stages of degeneration as well. The interstitium contains
collagen and basal lamina-like material (arrowheads).
V, blood vessel. C and D, high
magnification of myocytes from TG animals in various stages of
degeneration. C, a small portion of this cell is completely
devoid of sarcomeric organization and contains scattered electron-dense
material. Other parts of the myocyte show irregular accumulations of
Z-band-like material (arrows), distended T-tubules, and
small myelin figures (+). Note the collagen fibers in the interstitium
(arrowheads). D, a fragment of a partially
degenerated myocyte showing normal looking sarcomeres adjacent to an
area with scattered amorphous material of various electron density,
remnants of sarcoplasmic reticulum, and no mitochondria. The
interstitium contains collagen (arrowheads). The
abnormalities are representative of multiple grids obtained from
sections derived from three 10-week-old animals. A less detailed
analysis on hearts derived from the other high expressing line, line
35, revealed similar deficits.2
|
|
Molecular Markers of Hypertrophy Show a Dose Response--
Based
upon the histological analyses, it appeared that the LV of the TG
hearts might be mildly aberrant, although no increases in the LV free
wall weights could be detected (Table I). Based upon our experience
with a number of models, molecular markers of hypertrophy are often
elevated in the absence of any detectable histological changes. Indices
of the hypertrophic response at the molecular level were determined by
transcript analyses of LVs derived from high and low expressing lines
(lines 21 and 42, respectively) and compared with transcript levels in
the RLC2v(wt) overexpressor as well as with NTG hearts. Transcript
levels of ANF, -skeletal actin and -MyHC in line 21 animals were
significantly elevated when compared with line 42 animals as well as
the NTG and RLC2v(wt) controls (Fig. 6).
Thus, both TG lines show activation of the hypertrophic markers, and a
dose-dependent response is observed, in that the magnitude
of the response is consistent with the degree of RLC2v replacement with
the nonphosphorylatable species. Analyses of the transcripts for
phospholamban and sarcoplasmic reticulum ATPase, which can be
down-regulated during heart failure, reveal only very modest decreases,
indicating that these hearts remained quite healthy and show no signs
of decompensating into failure. No sign of a hypertrophic response at
the molecular level could be discerned in the RLC2v(wt)-overexpressing
line, indicating that isoform replacement in the atria and/or increased
levels of total RLC2v transcript in all four cardiac compartments were not responsible for the observed phenotype.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 6.
Hypertrophic and failure responses at the
transcriptional level. Ventricular expression of the indicated
transcripts was examined in adults from lines 42 and 21 (low and high
expressors, respectively) and compared with RNAs derived from both NTG
and RLC2v(wt) transgenic hearts. LV RNA was analyzed by hybridization
to dot blots with transcript-specific oligonucleotide probes. Data were
quantitated using a PhosphorImager. In all cases but ANF, values were
normalized to glyceraldehyde-3-phosphate dehydrogenase loading and
expressed as a -fold increase/decrease relative to NTG values. Note
that in all cases, RNA derived from RLC2v(wt) did not differ from NTG
controls. For ANF, values for line 21 were normalized to line 42 expression levels because ANF was not detected above background in the
NTG animals. RNAs were derived from three males/females from each line.
Statistical significance was determined using Student's t
test. The error bars indicate S.E.
(n = 3). *, p < 0.05.
|
|
Calcium Sensitivity of Force Development--
In skeletal muscle,
RLC2v phosphorylation results in increased sensitivity to activating
Ca2+ levels, leading to a leftward shift in the
force-Ca2+ curve. In line 21 mice, RLC2v cannot be
phosphorylated. To test the effect of this change on fiber
Ca2+ sensitivity, skinned fiber bundles from LV papillary
muscles were isolated from 8-week-old TG (line 21) and NTG hearts. At this stage of development, the pathological and histological changes have not yet occurred. Under normal isolation conditions, the fibers as
isolated are completely dephosphorylated. However, treatment with MLCK
results in approximately 50% of RLC2v being phosphorylated. This was
confirmed by performing Western blots on proteins derived from the NTG
fiber bundles before and after kinase treatment, using antibody
specific for RLC2v. Kinase treatment resulted in approximately 50%
phosphorylation of endogenous RLC2v, and no phosphorylation could be
observed in the RLC2v(P ) fibers.2
Force production in response to increasing Ca2+ levels was
measured under the dephosphorylated conditions and also following MLCK
treatment (Fig. 7). There were no
significant differences in pCa-force relationships between
the first and the second contraction in the control protocol without
any calmodulin or MLCK (see "Experimental Procedures"), indicating
that the kinase protocol itself did not alter fiber response to
Ca2+ (data not shown). When TG and NTG fibers were compared
before MLCK treatment (dephosphorylated) the curves were identical,
indicating that TG fibers behave normally under dephosphorylated
conditions. After MLCK treatment, when the degree of RLC2v
phosphorylation would differ between the NTG and TG animals, NTG
animals show increased Ca2+ sensitivity as indicated by a
leftward shift in the force-Ca2+ curve (Fig. 7,
A and C). The magnitude of this response is
similar to data obtained using skinned fibers isolated from rabbit
ventricle (7). In contrast, in the TG fibers, a leftward shift in the force-Ca2+ curve after kinase treatment did not occur (Fig.
7, B and D). Similar differences were seen in the
pCa-Mg2+-ATPase activity curves, with a leftward
shift (increase in sensitivity) occurring in the NTG fibers (Fig.
7E) and no changes presenting in the RLC2v(P ) (Fig.
7F). These data confirm that the RLC2v(P ) fibers cannot be
phosphorylated and, by this mechanism, cannot exhibit the shifts in
force development or Mg2+-ATPase activity as a function of
Ca2+.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 7.
Calcium activation of isolated ventricular
fibers. The ability of NTG (A, C, and
E) and line 21 TG fibers (B, D, and
F) to develop force as a function of [Ca2+]
and treatment with MLCK was measured in isolated skinned fibers as
described under "Experimental Procedures." The NTG fibers, when
treated with MLCK, exhibit increased sensitivity to Ca2+.
Force (A, B), normalized force (C,
D), and Mg2+-ATPase activity (E, F) are graphed
as a function of pCa. Line 21 TG fibers show no changes in
Ca2+ sensitivity as a result of MLCK treatment. Each fiber
set (n = 4) was derived from four 8-9-week-old
animals, and statistical significance was determined using the paired
t test except for the Mg2+-ATPase activity,
where statistical significance was determined using Student's
t test. *, p < 0.05; **, p < 0.01.
|
|
Responses to an Inotropic Stimulus--
What is the mechanistic
basis of the development of the phenotype seen in the RLC2v(P ) mice?
The fiber data indicate probable changes, in vivo, of
tension development as a function of Ca2+ concentration.
Thus, the end stage phenotype might reflect a functional deficit that
could arise as a result of the heart being unable to increase
contractile force in response to increased loading conditions or
chronotropic stimulation with increases in RLC2v phosphorylation
throughout the animal's life span. To test this hypothesis, we
measured increases in cardiac performance in response to -adrenergic
stimulation. Cohorts of RLC2v(wt) and RLC2v(P ) as well as NTG animals
were examined by utilizing the intact closed chest mouse model (32,
33). -Adrenergic stimulation was carried out by infusing increasing
concentrations of dobutamine (1-32 ng/min/g of body weight) over a
3-min period, with peak responses measured during the final 30 s
of the infusion period (Fig. 8). At the
end of the experiment, a propranolol bolus (100 ng/g of body weight)
was infused and cardiac function reevaluated in the absence of
-adrenergic stimulation.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 8.
Dobutamine dose-response relationships.
The closed chest intact mouse model and the dobutamine infusion
protocols have been described in detail (33). Each experimental set
(n = 5) consisted of 8-9-week-old animals.
Cardiovascular function was measured under control conditions (no
dobutamine) and under increasing -adrenergic stimulation. Three
cohorts, NTG, RLC2v(wt), and line 21 RLC2v(P ) were all subjected to
the same regimen, which included a series of 3-min infusions of
increasing concentrations of dobutamine and measuring the
cardiovascular indices in the last 30 s of each period in order to
obtain peak response. A propranolol bolus was used to terminate the
protocol so that function could be measured in the absence of
-adrenergic stimulation. Pressure signals from both the COBE and
Millar transducers were recorded using a MacLab 4/s data acquisition
system (AD Instruments, Milford, MA). The software directly determines
arterial systolic and diastolic pressure, mean arterial pressure, heart
rate, left ventricular systolic pressure, developed pressure, and both
positive (dP/dtmax) and negative
(dP/dtmin)
dP/dt. Data were analyzed using a mixed,
two-factor analysis of variance with repeated measures on the second
factor. When necessary, post hoc comparisons were performed
by single degree-of-freedom contrasts. D, *,
p 0.05; #, p 0.005.
|
|
Under nonstimulating conditions, there were no differences in the heart
rate (Fig. 8A), mean arterial pressure (Fig. 8B), left ventricular end diastolic pressure (Fig. 8E) and
dP/dtmax (Fig. 8C) among
RLC2v(P ), RLC2v(wt), and NTG animals. In NTG and RLC2v(wt) animals,
dobutamine increased the heart rate, dP/dt max, and dP/dt min
in a dose-dependent fashion (Fig. 8, A,
C, and D). In the RLC2v(P ) animals, the
response of dP/dt max to -adrenergic stimulation was significantly reduced when compared with
the first two cohorts (Fig. 8C), although the chronotropic response (heart rate) was essentially identical (Fig. 8A).
The absolute values of dP/dt min were
significantly lower in RLC2v(P ) animals under nonstimulated
conditions and at all levels of -adrenergic stimulation when
compared with NTG and RLC2v(wt) animals (Fig. 8D). There
were no differences in mean arterial pressure and LV end diastolic
pressure under nonstimulated conditions and at all levels of
-adrenergic stimulation in the three groups. Thus, the inotropic
responses in RLC2v(P ) animals are not due to alterations in afterload
and preload during -adrenergic stimulation or to differences in
heart rate. The myocardial contractile response to -adrenergic
stimulation in nonphosphorylatable RLC2v animals is reduced, indicating
that RLC2v phosphorylation can play a role in the positive inotropic
effect in response to -adrenergic stimulation.
Cardiac Remodeling in Older Mice--
To assess the contractile
and structural consequences the above changes might have on whole heart
function, mice (line 21) aged 16 weeks were subjected to
echocardiography (34, 35). In RLC2v(P ) TG mice, shortening fractions
were nearly the same. Consistent with the molecular and histologic
evidence, the mean left ventricular free wall thickness at end diastole
was increased in control animals compared with TGs, although the
difference did not reach statistical significance (0.085 ± 0.010 versus 0.104 ± 0.016 mm, respectively). No differences
could be discerned between the two groups' heart rates as measured in
resting, conscious animals using a computerized tail cuff apparatus
(581 ± 2 versus 592 ± 25 beats/min for the TG
and NTG mice, respectively). Apical four-chamber views using
two-dimensional guided color Doppler echocardiography were carried out
in RLC2v(P ) TG mice and compared with the RLC2v(wt) transgenics (Fig.
9). No abnormalities were observed in the
RLC2v(wt) transgenics, while the RLC2v(P ) mice show that altered
cardiac function is associated with severe tricuspid valve
insufficiency as evidenced by the regurgitation jet (Fig. 9A). It is likely that the tricuspid valve itself is not the
primary defect but that insufficiency stems from the leaflets becoming stretched apart as a result of RV dilation. In addition, thrombi were
identified in the RV.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 9.
Color Doppler echocardiographic
analysis. A, an apical chamber view from an RLC2v(P )
TG mouse showing the LV and dilated RV and right atrium as well as the
tricuspid valve. The severe tricuspid valve regurgitation
(TR) is indicated by the regurgitation jet into the right
atrium. B, a similar view derived from the RLC2v(wt)
overexpressing line and is indistinguishable from an NTG animal's
echocardiogram.2 This was highly reproducible (10/12,
16-week-old male/female animals from either line 21 or 35). None of the
15 nontransgenic or 12 transgenic RLC2v(wt) mice showed any signs of
TR.
|
|
 |
DISCUSSION |
The physiological effects of RLC2v phosphorylation in the mouse
heart were examined by overexpressing a nonphosphorylatable variant of
RLC2v. Previous reports suggested that light chain phosphorylation can
play a modulatory role in cardiac function in response to changing
loads and/or heart rate (6, 19, 36). In skeletal muscle there is clear
evidence that the degree of RLC phosphorylation plays a critical role
in determining Ca2+ sensitivity cross-bridge transitions
(37). Recently, insight into the structural basis for the observed
kinetic differences was obtained by examining negatively stained
skeletal thick filament preparations using a combination of electron
microscopy and optical diffraction techniques (38). These studies
showed that RLC phosphorylation probably increased the population of
the myosin heads that could form productive interactions with actin,
either by increasing the mobility of the head region or changing its
conformation. Multiple biochemical studies are consistent with the idea
that phosphorylation can potentiate productive interactions of the head
with the thin filament by physical movement away from the thick
filament "backbone" and closer to actin (4, 13, 39). We show here
that, over the early lifetime of the animal, the role of RLC
phosphorylation is critical for the maintenance of normal heart
function under sedentary conditions and that without the ability to
phosphorylate RLC2v, severe hypertrophy and dilation of the atria
occur, leading to poor cardiac performance. Previously, we
overexpressed wild type RLC2v in the mouse heart, resulting in complete
replacement of atrial RLC2a (17, 20, 31). That study showed that
overexpression of the ventricular isoform in the atrial compartment was
relatively benign. No overt changes in chamber size or overall
architecture of the heart could be discerned in those studies or the
studies above. Thus, the phenotype reported in the RLC2v(P ) mice is
due to expression of the mutated protein and not merely to
overexpression of RLC2v in the atrial compartment. It is interesting
that the most sensitive assay, the appearance of molecular markers of
hypertrophy, shows a dose response; i.e. line 42, in which
only low levels of transgene replacement occurs, shows much less
up-regulation of the transcripts measured, although the changes are
significant (Fig. 6). These data are consistent with the lack of a
detectable phenotype in these mice at the gross histological level
(Fig. 2). However, it may be that subtle histopathology will develop in
these mice over time, particularly if they are subjected to conditions
in which cardiovascular load is increased, such as defined exercise regimens (17).
The best characterized effect of RLC phosphorylation in striated muscle
is a leftward shift of the force-Ca2+ curves in skinned
fibers. When TG and NTG mice were analyzed, the NTG mice responded as
expected to the kinase treatment with a leftward shift of the curve.
There was no response to kinase treatment in the TG fibers as would be
expected with a phosphorylation-deficient protein. Importantly, there
were no significant differences between NTG and TG hearts under
dephosphorylated conditions, although it should be noted that the
degree of phosphorylation in the intact TG and NTG myocardia are not
identical. This observation suggests that myofibers from TG animals
have the capacity to behave normally and that the mutated protein does
not, by itself, structurally alter the basic fiber, leading to changes
in fiber function independent of its inability to become phosphorylated.
The long term effects associated with an inability to phosphorylate
RLC2v are profound. Dilation and hypertrophy of the atrial compartments
are common characteristics of the two high expressing lines. Remodeling
of the ventricles is subtler. Although the cellular indicators of
hypertrophy are present at the molecular level (activation of ANF,
-skeletal actin, and -MyHC), careful measurement of the LV free
wall/body weight showed no changes, although septal weights are
increased. Morphometric analyses of multiple fields in multiple
sections derived from three TG hearts revealed no statistical
differences.2 However, ultrastructural changes in both high
expressing lines were obvious with widely scattered, degenerating
myocytes apparent in multiple fields, changes in T-tubule organization,
and interstitial abnormalities. In addition to the obvious changes in
atrial morphology, we detected by histological analysis aspects of
myocyte degeneration, although no extensive fibrosis occurred. This is
probably due to the fact that the sarcolemmal membranes remain intact,
and there is a lack of necrosis; therefore, no obvious substantive fibrosis results.
By ablating the ability of RLC2v to be phosphorylated, the manner in
which the contractile apparatus responds to Ca2+,
particularly under conditions of increased load, was significantly altered. Obviously, there are other ways in which the cardiac myofilament can modulate its sensitivity to Ca2+ in
response to stress. Indeed, -adrenergic stimulation, which is
thought to be the physiologic pathway mediating RLC2v phosphorylation, can result in the phosphorylation of such proteins as troponin I, which
can also have major effects on the myofilament's contractile response
to Ca2+. The lack of the fibers' ability to "fine
tune" the heart's force production by phosphorylating RLC appears to
be critical over the lifetime of the animal. Under conditions where the
normal contractile apparatus could shift its
pCa2+-force curve to the left (increased force
development at normal levels of Ca2+), the transgenic
fibers will not respond appropriately.
Other factors may contribute to or underlie the dilation observed in
the echocardiographic analyses as well as the appearance of the
hypertrophic markers. For example, mutating the serines to alanines
could lead to subtle changes in light chain behavior and result in the
observed phenotype. This is an inherent limitation of the experimental
system. We believe this is unlikely, since charge is unchanged and the
substitutions are conservative.
Recently, it has become clear that Ca2+ levels can be
intimately involved with development of hypertrophy and may even be a primary regulator of the hypertrophic response (40). Phosphorylation of
RLC by MLCK is Ca2+/calmodulin-dependent, and
modulation of RLC phosphorylation might affect intracellular
Ca2+ levels at multiple levels. Inability to phosphorylate
RLC could trigger a response that could eventually affect intracellular Ca2+ levels. Consistent with this hypothesis, increasing
MLCK with decreasing RLC phosphorylation is implicated in the
hypertrophic response that occurs due to experimentally induced
myocardial infarction in rats (36). As the heart continues to remodel, it may be that alterations in Ca2+ transients occur in
order to maximize the ability to produce force. This, in turn, might
then activate the pathways leading to the end stage phenotype observed
in the mice. These are all testable hypotheses with this mouse model.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants HL56370, HL41496, HL56620, HL52318, HL60546, and HL56620; by a
grant from the Marion Merrell-Dow Foundation (to J. R.); and by an
American Physiological Society postdoctoral fellowship in mammalian
organ system physiology (to J. F.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
To whom correspondence should be addressed: Division of Molecular
Cardiovascular Biology, Children's Hospital Research Foundation, Cincinnati, OH 45229-3039. Tel.: 513-636-8098; Fax: 513-636-3852; E-mail: jeff.robbins@chmcc.org.
2
A. Sanbe, J. G. Fewell, J. Gulick, H. Osinska, J. Lorenz, D. G. Hall, L. A. Murray, T. R. Kimball, S. A. Witt, and J. Robbins, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
RLC, regulatory
myosin light chain;
RLC2v, ventricular regulatory myosin light chain;
MLCK, myosin light chain kinase;
TG, transgenic;
NTG, nontransgenic;
MyHC, myosin heavy chain;
RV, right ventricle;
LV, left ventricle;
ANF, atrial natriuretic factor;
PAGE, polyacrylamide gel electrophoresis;
BW, body weight.
 |
REFERENCES |
| 1.
|
Perrie, W. T.,
Smillie, L. B.,
and Perry, S. V.
(1973)
Biochem. J.
135,
151-164[Medline]
[Order article via Infotrieve]
|
| 2.
|
Stull, J. T.
(1980)
Adv. Cyclic Nucleotide Res.
13,
40-93
|
| 3.
|
Kamm, K. E.,
and Stull, J. T.
(1985)
Annu. Rev. Pharmacol. Toxicol.
25,
593-620[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Sweeney, H. L.,
Bowman, B. F.,
and Stull, J. T.
(1993)
Am. J. Physiol.
264,
C1085-C1095[Abstract/Free Full Text]
|
| 5.
|
Tuazon, P. T.,
Stull, J. T.,
and Traugh, J. A.
(1982)
Eur. J. Biochem.
129,
205-209[Medline]
[Order article via Infotrieve]
|
| 6.
|
Morano, I.,
Hofmann, F.,
Zimmer, M.,
and Ruegg, J. C.
(1985)
FEBS Lett.
189,
221-224[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Sweeney, H. L.,
and Stull, J. T.
(1986)
Am. J. Physiol.
250,
C657-C660[Abstract/Free Full Text]
|
| 8.
|
Moore, R. L.,
and Persechini, A.
(1990)
J. Cell. Physiol.
143,
257-262[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Metzger, J. M.,
Greaser, M. L.,
and Moss, R. L.
(1989)
J. Gen. Physiol.
93,
855-883[Abstract/Free Full Text]
|
| 10.
|
Sweeney, H. L.,
and Stull, J. T.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
414-418[Abstract/Free Full Text]
|
| 11.
|
Vandenboom, R. R.,
Grange, R. W.,
and Houston, M. E.
(1995)
Am. J. Physiol.
268,
C596-C601[Abstract/Free Full Text]
|
| 12.
|
Noland, T. J.,
and Kuo, J. F.
(1993)
Biochem. Biophys. Res. Commun.
193,
254-260[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Sweeney, H. L.,
Yang, Z.,
Zhi, G.,
Stull, J. T.,
and Trybus, K. M.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
1490-1494[Abstract/Free Full Text]
|
| 14.
|
Tohtong, R.,
Yamashita, H.,
Grahm, M.,
Haeberle, J.,
Simcox, A.,
and Maughan, D.
(1995)
Nature
374,
650-653[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Fitzsimons, D. P.,
Bodell, P. W.,
and Baldwin, K. M.
(1989)
J. Appl. Physiol.
67,
2447-2453[Abstract/Free Full Text]
|
| 16.
|
Fitzsimons, D. P.,
Bodell, P. W.,
and Baldwin, K. M.
(1990)
J. Appl. Physiol.
68,
2426-2433[Abstract/Free Full Text]
|
| 17.
|
Fewell, J. G.,
Osinska, H.,
Klevitsky, R.,
Ng, W.,
Sfyris, G.,
Bahrehmand, F.,
and Robbins, J.
(1997)
Am. J. Physiol.
273,
H1595-H1605[Abstract/Free Full Text]
|
| 18.
|
Akiyama, K.,
Akopian, G.,
Jinadasa, P.,
Gluckman, T. L.,
Terhakopian, A.,
Massey, B.,
and Bing, R. J.
(1997)
J. Mol. Cell. Cardiol.
29,
2641-2652[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Morano, I.
(1992)
Basic Res. Cardiol.
87,
129-141
|
| 20.
|
Palermo, J.,
Gulick, J.,
Colbert, M.,
Fewell, J.,
and Robbins, J.
(1996)
Circ. Res.
78,
504-509[Abstract/Free Full Text]
|
| 21.
|
Robbins, J.,
Palermo, J. J.,
and Rindt, H.
(1995)
Ann. N. Y. Acad. Sci.
752,
492-505[Medline]
[Order article via Infotrieve]
|
| 22.
|
Jones, W. K.,
Grupp, I. L.,
Doetschman, T.,
Grupp, G.,
Hewett, T.,
Boivin, G.,
Gulick, J.,
Ng, W. A.,
and Robbins, J.
(1996)
J. Clin. Invest.
8,
1906-1917
|
| 23.
|
Kirschbaum, B. J.,
Simoneau, J.,
Bar, A.,
Barton, P. J. R.,
Buckingham, M. E.,
and Pette, D.
(1989)
Eur. J. Biochem.
179,
23-29[Medline]
[Order article via Infotrieve]
|
| 24.
|
O'Farrell, P. H.
(1975)
J. Biol. Chem.
250,
4007-4021[Abstract/Free Full Text]
|
| 25.
|
Fewell, J. G.,
Hewett, T. E.,
Sanbe, A.,
Klevitsky, R.,
Hayes, E.,
Warshaw, D.,
Maughan, D.,
and Robbins, J.
(1998)
J. Clin. Invest.
101,
2630-2639[Medline]
[Order article via Infotrieve]
|
| 26.
|
Herring, B. P.,
Gallagher, P. J.,
and Stull, J. T.
(1992)
J. Biol. Chem.
267,
25945-25950[Abstract/Free Full Text]
|
| 27.
|
Dickinson, M. H.,
Hyatt, C. J.,
Lehmann, F. O.,
Moore, J. R.,
Reedy, M. C.,
Simcox, A.,
Tohtong, R.,
Vigoreaux, J. O.,
Yamashita, H.,
and Maughan, D. W.
(1997)
Biophys. J.
73,
3122-3134[Medline]
[Order article via Infotrieve]
|
| 28.
|
Ikebe, M.,
Hartshorne, D. J.,
and Elzinga, M.
(1986)
J. Biol. Chem.
261,
36-39[Abstract/Free Full Text]
|
| 29.
|
Amano, M.,
Ito, M.,
Kazushi, K.,
Fukata, Y.,
Chihara, K.,
Nakano, T.,
Matsuura, Y.,
and Kaibuchi, K.
(1996)
J. Biol. Chem.
271,
20246-20249[Abstract/Free Full Text]
|
| 30.
|
Venema, R. C.,
Raynor, R. L.,
Noland, T. A. J.,
and Kuo, J. F.
(1993)
Biochem. J.
294,
401-406
|
| 31.
|
Palermo, J.,
Gulick, J.,
Ng, W. A.,
Grupp, I. L.,
Grupp, G.,
and Robbins, J.
(1995)
Cell. Mol. Biol. Res.
41,
501-509[Medline]
[Order article via Infotrieve]
|
| 32.
|
Lorenz, J. N.,
and Robbins, J.
(1997)
Am. J. Physiol.
272,
H1137-H1146[Abstract/Free Full Text]
|
| 33.
|
Periasamy, M.,
Reed, T. D.,
Liu, L. H.,
Ji, Y.,
Loukianov, E.,
Paul, R. J.,
Nieman, M. L.,
Riddle, T.,
Duffy, J. J.,
Doetschman, T.,
Lorenz, J. N.,
and Shull, G. E.
(1999)
J. Biol. Chem.
274,
2556-2562[Abstract/Free Full Text]
|
| 34.
|
Hoit, B. D.,
Khoury, K. E. G.,
Ball, N.,
and Walsh, R. A.
(1995)
Circ. Res.
77,
632-637[Abstract/Free Full Text]
|
| 35.
|
Colbert, M. C.,
Hall, D. G.,
Kimball, T. R.,
Witt, S. A.,
Lorenz, J. N.,
Kirby, M. L.,
Hewett, T. E.,
Klevitsky, R.,
and Robbins, J.
(1997)
J. Clin. Invest.
100,
1958-1968[Medline]
[Order article via Infotrieve]
|
| 36.
|
Liu, X.,
Shao, Q.,
and Dhalla, N. S.
(1995)
J. Mol. Cell. Cardiol.
27,
2613-2631[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Patel, J. R.,
Diffee, G. M.,
and Moss, R. L.
(1996)
Biophys. J.
70,
2333-2340[Medline]
[Order article via Infotrieve]
|
| 38.
|
Levine, R. J.,
Kensler, R. W.,
Yang, Z.,
and Sweeney, H. L.
(1995)
Biophys. J.
68,
224S
|
| 39.
|
Adhikari, B. B.,
Somerset, J.,
Stull, J. T.,
and Fajer, P. G.
(1999)
Biochemistry
38,
3127-3132[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Molkentin, J. D.,
Lu, J.,
Antos, C.,
Markham, B.,
Richardson, J.,
Robbins, J.,
Grant, S. R.,
and Olson, E. N.
(1998)
Cell
93,
215-228[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. B. Scruggs, A. C. Hinken, A. Thawornkaiwong, J. Robbins, L. A. Walker, P. P. de Tombe, D. L. Geenen, P. M. Buttrick, and R. J. Solaro
Ablation of Ventricular Myosin Regulatory Light Chain Phosphorylation in Mice Causes Cardiac Dysfunction in Situ and Affects Neighboring Myofilament Protein Phosphorylation
J. Biol. Chem.,
February 20, 2009;
284(8):
5097 - 5106.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Kockskamper, M. Khafaga, M. Grimm, A. Elgner, S. Walther, A. Kockskamper, D. von Lewinski, H. Post, M. Grossmann, H. Dorge, et al.
Angiotensin II and myosin light-chain phosphorylation contribute to the stretch-induced slow force response in human atrial myocardium
Cardiovasc Res,
September 1, 2008;
79(4):
642 - 651.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Y. Chan, M. Takeda, L. E. Briggs, M. L. Graham, J. T. Lu, N. Horikoshi, E. O. Weinberg, H. Aoki, N. Sato, K. R. Chien, et al.
Identification of Cardiac-Specific Myosin Light Chain Kinase
Circ. Res.,
March 14, 2008;
102(5):
571 - 580.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Stelzer, J. R. Patel, and R. L. Moss
Acceleration of Stretch Activation in Murine Myocardium due to Phosphorylation of Myosin Regulatory Light Chain
J. Gen. Physiol.,
August 28, 2006;
128(3):
261 - 272.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Kehat, R. Heinrich, O. Ben-Izhak, H. Miyazaki, J. S. Gutkind, and A. Aronheim
Inhibition of basic leucine zipper transcription is a major mediator of atrial dilatation
Cardiovasc Res,
June 1, 2006;
70(3):
543 - 554.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Miller, B. M. Palmer, S. Ruch, L. A. Martin, G. P. Farman, Y. Wang, J. Robbins, T. C. Irving, and D. W. Maughan
The Essential Light Chain N-terminal Extension Alters Force and Fiber Kinetics in Mouse Cardiac Muscle
J. Biol. Chem.,
October 14, 2005;
280(41):
34427 - 34434.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Rajashree, B. C. Blunt, and P. A. Hofmann
Modulation of myosin phosphatase targeting subunit and protein phosphatase 1 in the heart
Am J Physiol Heart Circ Physiol,
October 1, 2005;
289(4):
H1736 - H1743.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Grey, A. Mery, and M. Puceat
Fine-tuning in Ca2+ homeostasis underlies progression of cardiomyopathy in myocytes derived from genetically modified embryonic stem cells
Hum. Mol. Genet.,
May 15, 2005;
14(10):
1367 - 1377.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Sanbe, J. James, V. Tuzcu, S. Nas, L. Martin, J. Gulick, H. Osinska, S. Sakthivel, R. Klevitsky, K. S. Ginsburg, et al.
Transgenic Rabbit Model for Human Troponin I-Based Hypertrophic Cardiomyopathy
Circulation,
May 10, 2005;
111(18):
2330 - 2338.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Vahebi, T. Kobayashi, C. M. Warren, P. P. de Tombe, and R. J. Solaro
Functional Effects of Rho-Kinase-Dependent Phosphorylation of Specific Sites on Cardiac Troponin
Circ. Res.,
April 15, 2005;
96(7):
740 - 747.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Sakthivel, N. L. Finley, P. R. Rosevear, J. N. Lorenz, J. Gulick, S. Kim, P. VanBuren, L. A. Martin, and J. Robbins
In Vivo and in Vitro Analysis of Cardiac Troponin I Phosphorylation
J. Biol. Chem.,
January 7, 2005;
280(1):
703 - 714.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Grimm, P. Haas, B. Willipinski-Stapelfeldt, W.-H. Zimmermann, T. Rau, K. Pantel, M. Weyand, and T. Eschenhagen
Key role of myosin light chain (MLC) kinase-mediated MLC2a phosphorylation in the {alpha}1-adrenergic positive inotropic effect in human atrium
Cardiovasc Res,
January 1, 2005;
65(1):
211 - 220.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Krenz and J. Robbins
Impact of beta-myosin heavy chain expression on cardiac function during stress
J. Am. Coll. Cardiol.,
December 21, 2004;
44(12):
2390 - 2397.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Hartshorne, M. Ito, and F. Erdodi
Role of Protein Phosphatase Type 1 in Contractile Functions: Myosin Phosphatase
J. Biol. Chem.,
September 3, 2004;
279(36):
37211 - 37214.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. H. Goldspink, D. E. Montgomery, L. A. Walker, D. Urboniene, R. D. McKinney, D. L. Geenen, R. J. Solaro, and P. M. Buttrick
Protein Kinase C{epsilon} Overexpression Alters Myofilament Properties and Composition During the Progression of Heart Failure
Circ. Res.,
August 20, 2004;
95(4):
424 - 432.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Sanbe, J. Gulick, M. C. Hanks, Q. Liang, H. Osinska, and J. Robbins
Reengineering Inducible Cardiac-Specific Transgenesis With an Attenuated Myosin Heavy Chain Promoter
Circ. Res.,
April 4, 2003;
92(6):
609 - 616.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Kobayashi, S. Horinaka, S.-i. Mita, S. Nakano, T. Honda, K. Yoshida, T. Kobayashi, and H. Matsuoka
Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts
Cardiovasc Res,
September 1, 2002;
55(4):
757 - 767.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Li, M. Puceat, C. Perez-Terzic, A. Mery, K. Nakamura, M. Michalak, K.-H. Krause, and M. E. Jaconi
Calreticulin reveals a critical Ca2+ checkpoint in cardiac myofibrillogenesis
J. Cell Biol.,
July 8, 2002;
158(1):
103 - 113.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N.-O. Ku, S. Michie, E. Z. Resurreccion, R. L. Broome, and M. B. Omary
Keratin binding to 14-3-3 proteins modulates keratin filaments and hepatocyte mitotic progression
PNAS,
April 2, 2002;
99(7):
4373 - 4378.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. F Bueno, E. van Rooij, J. D Molkentin, P. A Doevendans, and L. J De Windt
Calcineurin and hypertrophic heart disease: novel insights and remaining questions
Cardiovasc Res,
March 1, 2002;
53(4):
806 - 821.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Suematsu, S. Satoh, S. Kinugawa, H. Tsutsui, S. Hayashidani, R. Nakamura, K. Egashira, N. Makino, and A. Takeshita
{alpha}1-Adrenoceptor-Gq-RhoA signaling is upregulated to increase myofibrillar Ca2+ sensitivity in failing hearts
Am J Physiol Heart Circ Physiol,
August 1, 2001;
281(2):
H637 - H646.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Wang, H. Osinska, G. W. Dorn II, M. Nieman, J. N. Lorenz, A. M. Gerdes, S. Witt, T. Kimball, J. Gulick, and J. Robbins
Mouse Model of Desmin-Related Cardiomyopathy
Circulation,
May 15, 2001;
103(19):
2402 - 2407.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. P. Herring, S. Dixon, and P. J. Gallagher
Smooth muscle myosin light chain kinase expression in cardiac and skeletal muscle
Am J Physiol Cell Physiol,
November 1, 2000;
279(5):
C1656 - C1664.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Sanbe, D. Nelson, J. Gulick, E. Setser, H. Osinska, X. Wang, T. E. Hewett, R. Klevitsky, E. Hayes, D. M. Warshaw, et al.
In Vivo Analysis of an Essential Myosin Light Chain Mutation Linked to Familial Hypertrophic Cardiomyopathy
Circ. Res.,
August 18, 2000;
87(4):
296 - 302.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Murphy, H. Kögler, D. Georgakopoulos, J. L. McDonough, D. A. Kass, J. E. Van Eyk, and E. Marbán
Transgenic Mouse Model of Stunned Myocardium
Science,
January 21, 2000;
287(5452):
488 - 491.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
A. Sanbe, J. Gulick, J. Fewell, and J. Robbins
Examining the in Vivo Role of the Amino Terminus of the Essential Myosin Light Chain
J. Biol. Chem.,
August 24, 2001;
276(35):
32682 - 32686.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N.-O. Ku, S. Michie, E. Z. Resurreccion, R. L. Broome, and M. B. Omary
Keratin binding to 14-3-3 proteins modulates keratin filaments and hepatocyte mitotic progression
PNAS,
April 2, 2002;
99(7):
4373 - 4378.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Lin, W. A. Owens, S. Chen, M. E. Stevens, S. Kesteven, J. F. Arthur, E. A. Woodcock, M. P. Feneley, and R. M. Graham
Targeted {alpha}1A-Adrenergic Receptor Overexpression Induces Enhanced Cardiac Contractility but not Hypertrophy
Circ. Res.,
August 17, 2001;
89(4):
343 - 350.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|